Literature DB >> 9186666

Rheumatoid factor autoantibodies in health and disease.

R A Mageed1, M Børretzen, S P Moyes, K M Thompson, J B Natvig.   

Abstract

Recent advances in molecular biological and human cell hybridization technology have significantly advanced the knowledge of mechanisms that underlie human rheumatoid factor (RF) production. These advances have provided insight into the etiopathogenesis of synovial inflammation and lymphocyte recruitment in rheumatoid arthritis (RA) joints. We have examined the mechanisms that lead to RF production in RA patients and those that regulate RF production in normals. The studies revealed structural features that distinguish RF produced in normals from those produced in RA synovial tissue. There are significant differences in the use of VL and VH genes between the two RF populations. Furthermore, IgV genes encoding synovial RF in RA have extensive evidence for nucleotide changes, leading to amino acid replacement in the complementarity determining regions (CDRs). In addition, RF produced in RA synovia show evidence for affinity maturation, isotype switch to IgG RF, and repertoire shift indicative of a continued recruitment of B cells. Together with computer modeling and crystallographic studies, our data suggest that the mechanisms that operate on RF selection in RA synovia are similar to immune responses to exogenous antigens. In contrast, RF established from human immunized donors (HID) are characterized by a very low ratio of replacement to silent (R:S) nucleotide changes in the CDR1+2. In addition, there is little increase in affinity with increasing numbers of mutations. There is thus evidence for regulatory mechanisms that limit affinity maturation of RF in normals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186666     DOI: 10.1111/j.1749-6632.1997.tb52071.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

Review 1.  Antibody-dependent and -independent mechanisms of inflammatory arthritis.

Authors:  Margaret H Chang; Peter A Nigrovic
Journal:  JCI Insight       Date:  2019-03-07

2.  Immunoglobulin G structure and rheumatoid factor epitopes.

Authors:  Sheila Lefoli Maibom-Thomsen; Nicole Hartwig Trier; Bettina Eide Holm; Kirsten Beth Hansen; Morten Ib Rasmussen; Anna Chailyan; Paolo Marcatili; Peter Højrup; Gunnar Houen
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

3.  Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice.

Authors:  Hiroshi Hata; Noriko Sakaguchi; Hiroyuki Yoshitomi; Yoichiroh Iwakura; Kenji Sekikawa; Yoshiaki Azuma; Chieko Kanai; Eiko Moriizumi; Takashi Nomura; Takashi Nakamura; Shimon Sakaguchi
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

4.  Human IgG Fc-binding phage antibodies constructed from synovial fluid CD38+ B cells of patients with rheumatoid arthritis show the imprints of an antigen-dependent process of somatic hypermutation and clonal selection.

Authors:  W J E Van Esch; C C Reparon-Schuijt; H J Hamstra; C Van Kooten; T Logtenberg; F C Breedveld; C L Verweij
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

Review 5.  Cell-cell interactions in synovitis: antigen presenting cells and T cell interaction in rheumatoid arthritis.

Authors:  T Aarvak; J B Natvig
Journal:  Arthritis Res       Date:  2000-10-27

6.  A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis.

Authors:  Cristina Regueiro; Luis Rodriguez-Rodriguez; Raquel Lopez-Mejias; Laura Nuño; Ana Triguero-Martinez; Eva Perez-Pampin; Alfonso Corrales; Alejandro Villalba; Yolanda Lopez-Golan; Lydia Abasolo; Sara Remuzgo-Martínez; Ana M Ortiz; Eva Herranz; Ana Martínez-Feito; Carmen Conde; Antonio Mera-Varela; Alejandro Balsa; Isidoro Gonzalez-Alvaro; Miguel Ángel González-Gay; Benjamín Fernandez-Gutierrez; Antonio Gonzalez
Journal:  Sci Rep       Date:  2020-02-25       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.